{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T07:33:16Z","timestamp":1771054396509,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Debra Norge"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This article presents evidence-based Clinical Practice Guidelines (CPG) for the provision of healthcare services to address sexuality for people living with epidermolysis bullosa (EB). Currently, a lack of EB-specific research limits these services to sexual health assessment and intervention strategies designed for the general population. Due to the unique challenges of EB, a rare skin-fragility condition causing blistering responses to minor skin trauma and other systemic and secondary complications, condition-specific strategies are needed to support people with EB in achieving valued sexual lifestyles. This CPG represents the work of an international panel comprised of thirteen members including a medical doctor, nurses, psychologists, a social worker, an occupational therapist, and patient population involvement members living with EB. It describes the development of EB-specific recommendations for two primary domains of assessment and intervention related to sexuality: psychosocial and mechanical. Following a rigorous evidence-based guideline development process, this CPG establishes the first internationally actionable clinical practice recommendations for sexuality-related assessment and intervention for this population. Future research priorities are identified. Supplemental materials included provide additional support to clinicians in developing the necessary understanding and skills to promote equity and efficacy in this care domain.<\/jats:p>","DOI":"10.1186\/s13023-020-01640-0","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T19:04:06Z","timestamp":1609959846000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Supporting sexuality for people living with epidermolysis bullosa: clinical practice guidelines"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1362-2004","authenticated-orcid":false,"given":"Alex","family":"King","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Humphrey","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Popenhagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florencia","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Purvis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida","family":"Steinlein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mia","family":"Werkentoft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Lightfoot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Lahat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalsoom","family":"Begum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"issue":"4","key":"1640_CR1","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/bjd.18921","volume":"183","author":"C Has","year":"2020","unstructured":"Has C, Bauer JW, Bodemer C, Bolling M, Bruckner-Tuderman L, Diem A, et al. Consensus re-classification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol. 2020;183(4):614\u201327.","journal-title":"Br J Dermatol."},{"issue":"1","key":"1640_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13023-019-1059-8","volume":"14","author":"JM Chan","year":"2019","unstructured":"Chan JM, Weisman A, King A, Maksomski S, Shotwell C, Bailie C, et al. Occupational therapy for epidermolysis bullosa: clinical practice guidelines. Orphanet J Rare Dis. 2019;14(1):129.","journal-title":"Orphanet J Rare Dis"},{"key":"1640_CR3","unstructured":"World Health Organization: defining sexual health. https:\/\/www.who.int. 2006a, updated 2010. Accessed 4 May 2020."},{"key":"1640_CR4","volume-title":"Disability, intimacy, and sexual health: a social work perspective","author":"KL Linton","year":"2017","unstructured":"Linton KL, Rueda HA, et al. Disability, intimacy, and sexual health: a social work perspective. Washington: NASW Press; 2017."},{"key":"1640_CR5","unstructured":"The grading of recommendations assessment, development and evaluation (GRADE). The GRADE Working Group; 2004 [updated 2020; cited July 2020]. http:\/\/www.gradeworkinggroup.org\/. Accessed 1 Sept 2019."},{"key":"1640_CR6","unstructured":"The AGREE Next Steps Consortium. Appraisal of guidelines for research & evaluation instrument (AGREE-II). The AGREE Research Trust; 2009 [updated 2017; cited July 2020]. https:\/\/www.agreetrust.org\/wp-content\/uploads\/2017\/12\/AGREE-II-Users-Manual-and-23-item-Instrument-2009-Update-2017.pdf. Accessed 15 May 2020."},{"issue":"6","key":"1640_CR7","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/mgg3.315","volume":"5","author":"C von der Lippe","year":"2017","unstructured":"von der Lippe C, Diesen PS, Feragen KB. Living with a rare disorder: a systematic review of the qualitative literature. Mol Genet Genomic Med. 2017;5(6):758\u201373.","journal-title":"Mol Genet Genomic Med"},{"issue":"8","key":"1640_CR8","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/j.1365-4632.2007.03311.x","volume":"46","author":"AW Lucky","year":"2007","unstructured":"Lucky AW, Pfendner E, Pillay E, Paskel J, Weiner M, Palisson F. Psychosocial aspects of epidermolysis bullosa: proceedings of the II nd international symposium on Epidermolysis Bullosa, Santiago, Chile, 2005. Int J Dermatol. 2007;46(8):809\u201314.","journal-title":"Int J Dermatol"},{"key":"1640_CR9","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/j.1365-4632.2007.03315.x","volume":"46","author":"AW Lucky","year":"2007","unstructured":"Lucky AW, Palisson F. Overview of the proceedings of the iind international symposium on Epidermolysis Bullosa, Santiago, Chile, 2005. Int J Dermatol. 2007;46:779\u201380.","journal-title":"Int J Dermatol"},{"issue":"1","key":"1640_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.clindermatol.2011.11.009","volume":"31","author":"P Magin","year":"2013","unstructured":"Magin P. Appearance-related bullying and skin disorders. Clin Dermatol. 2013;31(1):66\u201371.","journal-title":"Clin Dermatol"},{"issue":"2","key":"1640_CR11","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.det.2010.01.007","volume":"28","author":"AE Martinez","year":"2010","unstructured":"Martinez AE, Allgrove J, Brain C. Growth and pubertal delay in patients with epidermolysis bullosa. Dermatol Clin. 2010;28(2):357\u20139, xii.","journal-title":"Dermatol Clin"},{"issue":"4","key":"1640_CR12","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1037\/1040-3590.15.4.532","volume":"15","author":"U Stangier","year":"2003","unstructured":"Stangier U, Ehlers A, Gieler U. Measuring adjustment to chronic skin disorders: validation of a self-report measure. Psychol Assess. 2003;15(4):532\u201349.","journal-title":"Psychol Assess"},{"issue":"5","key":"1640_CR13","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1177\/1359105310387954","volume":"16","author":"EF Williams","year":"2011","unstructured":"Williams EF, Gannon K, Soon K. The experiences of young people with Epidermolysis Bullosa Simplex: a qualitative study. J Health Psychol. 2011;16(5):701\u201310.","journal-title":"J Health Psychol"},{"key":"1640_CR14","unstructured":"Adni T, Martin K, Mudge E. The psychosocial impact of chronic wounds on patients with severe epidermolysis bullosa. J Wound Care. 2012;21(11):528, 30\u20136, 38."},{"issue":"6","key":"1640_CR15","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1177\/1049732311400431","volume":"21","author":"E Dures","year":"2011","unstructured":"Dures E, Morris M, Gleeson K, Rumsey N. The psychosocial impact of epidermolysis bullosa. Qual Health Res. 2011;21(6):771\u201382.","journal-title":"Qual Health Res"},{"issue":"1","key":"1640_CR16","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.4081\/hpr.2013.649","volume":"1","author":"E Dures","year":"2013","unstructured":"Dures E, Rumsey N, Morris M, Gleeson K. A cross sectional, observational survey to assess levels and predictors of psychological wellbeing in adults with Epidermolysis Bullosa. Health Psychol Res. 2013;1(1):e4.","journal-title":"Health Psychol Res"},{"issue":"3","key":"1640_CR17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jaad.2009.03.053","volume":"61","author":"JD Fine","year":"2009","unstructured":"Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs. J Am Acad Dermatol. 2009a;61(3):387\u2013402 quiz 3\u20134.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1640_CR18","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/j.1365-2133.2009.09347.x","volume":"161","author":"JW Frew","year":"2009","unstructured":"Frew JW, Martin LK, Nijsten T, Murrell DF. Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument. Br J Dermatol. 2009;161(6):1323\u201330.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1640_CR19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1046\/j.1365-2133.2002.04607.x","volume":"146","author":"HM Horn","year":"2002","unstructured":"Horn HM, Tidman MJ. The clinical spectrum of dystrophic epidermolysis bullosa. Br J Dermatol. 2002a;146(2):267\u201374.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1640_CR20","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/j.1365-2133.2009.09306.x","volume":"161","author":"S Tabolli","year":"2009","unstructured":"Tabolli S, Sampogna F, Di Pietro C, Paradisi A, Uras C, Zotti P, et al. Quality of life in patients with epidermolysis bullosa. Br J Dermatol. 2009;161(4):869\u201377.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1640_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2340\/00015555-0376","volume":"88","author":"C van Scheppingen","year":"2008","unstructured":"van Scheppingen C, Lettinga AT, Duipmans JC, Maathuis CG, Jonkman MF. Main problems experienced by children with epidermolysis bullosa: a qualitative study with semi-structured interviews. Acta Derm Venereol. 2008;88(2):143\u201350.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"1640_CR22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1586\/erp.09.23","volume":"9","author":"MK Basra","year":"2009","unstructured":"Basra MK, Shahrukh M. Burden of skin diseases. Expert Rev Pharmacoecon Outcomes Res. 2009;9(3):271\u201383.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"1640_CR23","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1365-2133.2011.10592.x","volume":"166","author":"V Colomb","year":"2012","unstructured":"Colomb V, Bourdon-Lannoy E, Lambe C, Sauvat F, Hadj Rabia S, Teillac D, et al. Nutritional outcome in children with severe generalized recessive dystrophic epidermolysis bullosa: a short- and long-term evaluation of gastrostomy and enteral feeding. Br J Dermatol. 2012;166(2):354\u201361.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1640_CR24","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1046\/j.1365-2133.1996.120855.x","volume":"134","author":"L Haynes","year":"1996","unstructured":"Haynes L, Atherton DJ, Ade-Ajayi N, Wheeler R, Kiely EM. Gastrostomy and growth in dystrophic epidermolysis bullosa. Br J Dermatol. 1996;134(5):872\u20139.","journal-title":"Br J Dermatol"},{"issue":"8","key":"1640_CR25","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1046\/j.1365-2230.2002.01121.x","volume":"27","author":"HM Horn","year":"2002","unstructured":"Horn HM, Tidman MJ. Quality of life in epidermolysis bullosa. Clin Exp Dermatol. 2002b;27(8):707\u201310.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"1640_CR26","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1177\/1049732314549029","volume":"25","author":"LD Hubbard","year":"2015","unstructured":"Hubbard LD, Mayre-Chilton K. Quality of life among adults with epidermolysis bullosa living with a gastrostomy tube since childhood. Qual Health Res. 2015;25(3):310\u20139.","journal-title":"Qual Health Res"},{"issue":"5 Pt 1","key":"1640_CR27","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1097\/01.ju.0000143200.86683.2c","volume":"172","author":"JD Fine","year":"2004","unstructured":"Fine JD, Johnson LB, Weiner M, Stein A, Cash S, DeLeoz J, et al. Genitourinary complications of inherited epidermolysis bullosa: experience of the national epidermolysis bullosa registry and review of the literature. J Urol. 2004;172(5 Pt 1):2040\u20134.","journal-title":"J Urol"},{"issue":"3","key":"1640_CR28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jaad.2009.03.052","volume":"61","author":"JD Fine","year":"2009","unstructured":"Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues. J Am Acad Dermatol. 2009b;61(3):367\u201384 quiz 85\u201386.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1640_CR29","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1365-2230.2011.04179.x","volume":"37","author":"T Hanafusa","year":"2012","unstructured":"Hanafusa T, Tamai K, Umegaki N, Yamaguchi Y, Fukuda S, Nishikawa Y, et al. The course of pregnancy and childbirth in three mothers with recessive dystrophic epidermolysis bullosa. Clin Exp Dermatol. 2012;37(1):10\u20134.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"1640_CR30","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10880-010-9205-4","volume":"17","author":"F Margari","year":"2010","unstructured":"Margari F, Lecce PA, Santamato W, Ventura P, Sportelli N, Annicchiarico G, et al. Psychiatric symptoms and quality of life in patients affected by epidermolysis bullosa. J Clin Psychol Med Settings. 2010;17(4):333\u20139.","journal-title":"J Clin Psychol Med Settings"},{"key":"1640_CR31","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN). SIGN 50: a guideline developer\u2019s handbook. NHS Quality Improvement Scotland; 2007 [updated 2019; cited July 2020]. https:\/\/www.sign.ac.uk\/assets\/sign50_2011.pdf. Accessed 1 Sept 2019."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01640-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-020-01640-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01640-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T22:09:20Z","timestamp":1610230160000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01640-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1640"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01640-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]},"assertion":[{"value":"7 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All CPG panel members and reviewers completed written conflict of interest declarations. With one exception (DP), this panel of researchers claims no financial conflicts of interest. DP declared employment with Starship Children\u2019s Hospital, New Zealand, as well as self-employment as a dermatologist serving on a subcommittee advising Pharmac (pharmaceutical advisory board for New Zealand government) receiving honoraria from Galderma and Johnson and Johnson. All reviewers declared no potential conflicts of interest with respect to the publication of this guideline. Recommendations in these guidelines do not constitute a single approach or standard of medical care. Variations to the recommendations provided may be indicated on an individual, organizational, or other basis. Considerable efforts have been made by this panel to ensure content is accurate and up-to-date. Users of these guidelines are strongly recommended to confirm the accuracy, validity, and relevance of all information provided. The authors, DEBRA Norge, or DEBRA International accept no responsibility for any inaccuracies, information perceived as misleading, or the success of any treatment regimen detailed in the guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}